CNS SIDE EFFECTS OF ANTIHYPERTENSIVE THERAPIES

这项研究旨在评估中枢神经系统的副作用， 抗高血压治疗的手段，多方面的，心理生物学 评估方法。 特别令人感兴趣的是 睡眠结构、认知和知觉运动治疗 表现、情绪状态和性功能。 此外，潜在的 外周（循环和代谢）过程作为 将研究疲劳和其它CNS效应。 为了评估 在长期用药和未治疗患者中的治疗效果，3 建议进行补充研究： 研究I将包括一个匹配的比较，其中48名男性高血压患者， 接受长期普萘洛尔治疗的患者将与 可乐定组的患者。 将选择两个队列组 在每种药物条件下进行评价， 将包括有症状和无症状的患者。 的目的 研究旨在确定与患者相关的CNS效应模式， 疲劳和困倦的抱怨，并测试有关的假设， 调解这些影响。 研究II是一项前瞻性、实验性 评价80例未经治疗的男性高血压患者，其中48例 将被随机分配到药物组（普萘洛尔，可乐定， 安慰剂），32例患者接受非药物治疗。 完成 心理生物学评估将在每次 治疗阶段。 研究III包括研究II的部分复制， 其中患有单纯收缩期高血压的老年男性将接受 普萘洛尔、安慰剂或非药物治疗。 后者的研究 将研究肾上腺素能抑制的生物行为后遗症， 未接受治疗的男性患者的非药物治疗。 总之，这些研究将提供一个深入的评价中枢神经系统 与抗高血压治疗相关的副作用， 在高血压临床管理中的价值。

The proposed research seeks to evaluate CNS side effects of antihypertensive therapies by means of a multidimensional, psychobiological assessment methodology. Of particular interest are the effects of treatment on sleep architecture, cognitive and perceptual-motor performance, mood state, and sexual function. Additionally, the potential role of peripheral (circulatory and metabolic) processes as determinants of fatigue and other CNS effects will be investigated. In order to assess the effects of treatment in chronically medicated and untreated patients, three complimentary studies are proposed: Study I will consist of a matched comparison in which 48 male hypertensive patients receiving long-term propranolol therapy will be compared to a matched group of patients on clonidine. Two cohort groups will be selected for evaluation within each drug condition, and an equal number of symptomatic and asymptomatic patients will be included. The purpose of the study is to identify patterns of CNS effects associated with patient complaints of drowsiness and fatigue, and to test hypotheses concerning the mediation of these effects. Study II is a prospective, experimental evaluation of 80 untreated male hypertensive patients, in which 48 patients will be randomly assigned to pharmacological (propranolol, clonidine, placebo), and 32 patients to non-pharmacological treatment. Complete psychobiological assessments will be conducted before and after each treatment phase. Study III consists of a partial replication of Study II, in which elderly males with isolated systolic hypertension will receive propranolol, placebo, or non-pharmacological therapy. The latter studies will investigate biobehavioral sequellae of adrenergic-inhibiting and non-pharmacological therapies in untreated male patients. Taken together, these studies will provide an in-depth evaluation of CNS side effects associated with antihypertensive treatment, and will be of value in the clinical management of hypertension.